A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Conditions:   Solid Tumors;   Advanced Triple Negative Breast Cancer;   Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer;   Advanced Metastatic Castration-Resistant Prostate Cancer;   Advanced Platinum-Resistant Ovarian Cancer Interventions:   Drug: TRX518;   Drug: Cyclophosphamide;   Drug: Avelumab Sponsors:   Leap Therapeutics, Inc.;   Pfizer;   Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials